Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema - Reply

被引：10
|
作者：
Beck, TR
Baird, LG
机构：
[1] Dyax Corp, Business & Prod Dev, Cambridge, MA 02139 USA
[2] Dyax Corp, Dev, Cambridge, MA 02139 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2006年 / 117卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2005.10.044
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：477 / 477
页数：1
相关论文
共 50 条
  • [21] The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema
    Levy, Jerrold H.
    O'Donnell, Penrose S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (09) : 1077 - 1090
  • [22] DX-88/19: FINAL RESULTS FROM THE OPEN-LABEL CONTINUATION STUDY OF ECALLANTIDE FOR ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA.
    MacGinnitie, A. J.
    Lumry, W.
    Bernstein, J. A.
    Li, H. H.
    Riedl, M.
    Soteres, D. E.
    Craig, T. J.
    Stolz, L.
    Pullman, W. E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A11 - A11
  • [23] Development of C1-inhibitor antibodies in a patient with hereditary angioedema
    Seneviratne, Suranjith
    Manson, Ania
    Gurugama, Padmalal
    Eren, Efrem
    Goswami, Rajee
    Dziadzio, Magdalena
    Verma, Nisha
    Jolles, Stephen
    Roberts, Andrew
    Abdalla, Saad
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 174 : 28 - 28
  • [24] Pharmacodynamic Effect of DX-2930 on Plasma Kallikrein in Hereditary Angioedema Patients
    Davis-Lorton, Mark A.
    Busse, Paula J.
    Banerji, Aleena
    Shennak, Mustafa
    Lumry, William R.
    Wedner, H. James
    Jacobs, Joshua S.
    Baker, James W.
    Bernstein, Jonathan A.
    Lockey, Richard F.
    Li, H. Henry
    Craig, Timothy J.
    Marco-Cicardi
    Riedl, Marc A.
    Al-Ghazawi, Ahmad
    Soo, Carolyn
    Iarrobino, Ryan
    Sexton, Daniel
    TenHoor, Christopher
    Faucette, Ryan
    Biedenkapp, Joseph C.
    Chyung, Yung H.
    Adelman, Burt
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB252 - AB252
  • [25] Neuroprotective effect of plasma kallikirein inhibitor DX-88 on brain ischemia/reperfusion brain injury
    Bergamaschini, L
    Rossi, E
    Storini, C
    De Simoni, MG
    MOLECULAR IMMUNOLOGY, 2004, 41 (2-3) : 208 - 208
  • [26] ECALLANTIDE: A PLASMA KALLIKREIN INHIBITOR FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA
    Stolz, L. E.
    Horn, P. T.
    DRUGS OF TODAY, 2010, 46 (08) : 547 - 555
  • [27] Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor
    Schneider, Lynda
    Lumry, William
    Vegh, Arthur
    Williams, Anthony H.
    Schmalbach, Tess
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (02) : 416 - 422
  • [28] C1-esterase inhibitor antibodies in a patient with type 1 hereditary angioedema
    Seneviratne, S.
    Manson, A.
    Gurugama, P.
    Eren, E.
    Goswami, R.
    Dziadzio, M.
    Verma, N.
    Jolles, S.
    Roberts, A.
    Abdalla, S.
    ALLERGY, 2014, 69 : 487 - 487
  • [29] Interim results of EDEMA2, a multicenter, open-label, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema
    Lumry, W
    Ritchie, B
    Beck, T
    Morrison, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S179 - S179
  • [30] A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema
    Dona, Inmaculada
    Torres, Maria Jose
    ALLERGY, 2021, 76 (06) : 1619 - 1620
12345